These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 204304)

  • 21. Metabolism of prostaglandins in spontaneously hypertensive rats: NAD"-dependent 15-hydroxyprostaglandin dehydrogenase activity is decreased in kidney and increased in lung.
    Tai HH; Yuan B; Sun M
    Life Sci; 1979 Apr; 24(14):1275-80. PubMed ID: 224273
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
    Nemoz G; Prigent AF
    Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
    [No Abstract]   [Full Text] [Related]  

  • 23. Structural requirements for potent and selective inhibition of low-Km, cyclic-AMP-specific phosphodiesterases.
    Robertson DW; Boyd DB
    Adv Second Messenger Phosphoprotein Res; 1992; 25():321-40. PubMed ID: 1313265
    [No Abstract]   [Full Text] [Related]  

  • 24. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase from porcine kidney. I. Purification and partial characterization.
    Kung-Chao DT; Tai HH
    Biochim Biophys Acta; 1980 Jul; 614(1):1-13. PubMed ID: 7397198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro inhibition of cyclic 3' 5',-AMP-phosphodiesterase by a group of structural analogues of glaucine.
    Petkov V; Stancheva S
    Acta Physiol Pharmacol Bulg; 1980; 6(3):38-47. PubMed ID: 6269351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo myocardial effects of a cyclic AMP phosphodiesterase inhibitor structurally related to natural cardenolides.
    Prigent AF; Nemoz G; Roche M; Pacheco H
    Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):131-52. PubMed ID: 230791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of 3',5'-cyclic nucleotide 3'-phosphohydrolase by a novel 1',2'-cyclic nucleotide.
    Nair V; Wiechert RJ; Young DA
    J Cyclic Nucleotide Res; 1982; 8(3):181-90. PubMed ID: 6187785
    [No Abstract]   [Full Text] [Related]  

  • 28. Irreversible inhibition of calmodulin-sensitive cyclic nucleotide phosphodiesterase.
    Sullivan TA; Duemler BH; Kuttesch NJ; Keravis TM; Wells JN
    J Cyclic Nucleotide Protein Phosphor Res; 1986; 11(5):355-64. PubMed ID: 2442214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular, catalytic, and immunological characterization of NAD+-linked 15-hydroxyprostaglandin dehydrogenase.
    Tai HH; Liu Y; Tai CL; Yoden K; Shen RF
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():159-61. PubMed ID: 2936083
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of adenosine 3',5'-monophosphate phosphodiesterase by nicotinamide and its homologues in vitro.
    Shimoyama M; Kawai M; Nasu S; Shioji K; Hoshi Y
    Physiol Chem Phys; 1975; 7(2):125-32. PubMed ID: 239431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
    Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
    Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
    [No Abstract]   [Full Text] [Related]  

  • 32. 12-L-hydroxy-5,8,10-heptadecatrienoic acid (HHT) is an excellent substrate for NAD+-dependent 15-hydroxyprostaglandin dehydrogenase.
    Liu Y; Yoden K; Shen RF; Tai HH
    Biochem Biophys Res Commun; 1985 May; 129(1):268-74. PubMed ID: 4004878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromatographic behavior of cyclic 3',5'-nucleotide phosphodiesterases on columns of immobilized inhibitors.
    Mohindru A; Chenet A; Rhoads AR
    Biochemistry; 1978 Aug; 17(16):3297-304. PubMed ID: 80229
    [No Abstract]   [Full Text] [Related]  

  • 34. Cyclic AMP phosphodiesterase inhibitors depress production of plasminogen activator by Chinese hamster ovary cells.
    Mott DM; Fabisch PH; Sorof S
    Biochem Biophys Res Commun; 1976 Jun; 70(4):1150-6. PubMed ID: 182161
    [No Abstract]   [Full Text] [Related]  

  • 35. Interaction of calcium antagonists with cyclic AMP phosphodiesterases and calmodulin.
    Epstein PM; Fiss K; Hachisu R; Andrenyak DM
    Biochem Biophys Res Commun; 1982 Apr; 105(3):1142-9. PubMed ID: 6284165
    [No Abstract]   [Full Text] [Related]  

  • 36. Induction of motility in immature bovine spermatozoa by cyclic AMP phosphodiesterase inhibitors and seminal plasma.
    Hoskins DD; Hall ML; Munsterman D
    Biol Reprod; 1975 Sep; 13(2):168-76. PubMed ID: 177102
    [No Abstract]   [Full Text] [Related]  

  • 37. Phosphodiesterase inhibition as a mechanism for the diuretic activity of 1 ((tert-butylimino)methyl)-2-(3-indolyl)indoline hydrochloride (MJ-8592-1).
    Amer MS; Gomoll AW; McKinney GR
    Res Commun Chem Pathol Pharmacol; 1972 Sep; 4(2):467-76. PubMed ID: 4342315
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibition of the low Km cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone.
    Silver PJ; Lepore RE; O'Connor B; Lemp BM; Hamel LT; Bentley RG; Harris AL
    J Pharmacol Exp Ther; 1988 Oct; 247(1):34-42. PubMed ID: 2845058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclic AMP phosphodiesterase from human heart and drug action.
    Tanaka T; Masuoka H; Ito M; Nakano T; Naka M; Hidaka H
    Adv Second Messenger Phosphoprotein Res; 1992; 25():373-81. PubMed ID: 1313268
    [No Abstract]   [Full Text] [Related]  

  • 40. Pulmonary NAD+-linked 15-hydroxyprostaglandin dehydrogenase activity is decreased by cigarette smoking.
    Chang WC; Fukuda S; Tai HH
    Life Sci; 1984 Mar; 34(13):1261-8. PubMed ID: 6708729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.